Pathwork Diagnostics Looks to Collaborators To Validate TOO Test as it Awaits FDA’s OK

Pathwork Diagnostics plans to draw on partnerships and exhibitions to showcase its TOO test while the US Food and Drug Administration reviews it for 510 (k) clearance.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.